An At-Home Collection Device for Diabetes Risk Testing

Labcorp and Weavr teamed up for the development of the at-home-collection device.

MDDI Staff

May 17, 2022

1 Min Read
Image courtesy of Dima / Alamy Stock Photo

Labcorp has launched a product that has the potential to make it convenient for people to see whether they are at risk of developing diabetes.

The Burlington, NC-based company said its Labcorp OnDemand test measures hemoglobin A1c (HbA1c) from a small blood sample. The company is using a collection device from Weavr Health, a diagnostics company that provides remote biofluid collection devices to extend access to health and wellness testing.

Through an equity investment made by Labcorp, the device was co-developed for HbA1c by the two companies with Weavr remaining the device owner.

The device separates plasma and red blood cells, which allows a more in-depth, complex analysis of the sample. It was designed to enclose the sample to keep it contained, safe and stable for transport and testing. After collection, the device is returned to Labcorp via a prepaid FedEx envelope.

“Diabetes is a serious disease affecting millions of people in the United States,” said Dr. Brian Caveney, chief medical officer and president, Labcorp Diagnostics. “Our Labcorp OnDemand Diabetes Risk Test at-home collection kit now makes it easier for consumers to understand their diabetes risk and health status using an innovative and approved collection device. This test offers a convenient way for more people to manage their health and stay informed, so they can seek treatment that may lead to better health outcomes.”


Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like